Indian pharma firm Zydus gets USFDA nod to market Isoproterenol hydrochloride injections

Through an exchange filing, pharma company Zydus Lifesciences Limited has announced that it received the United States Food and Drug Administration's (USFDA) nod to manufacture and market Isoproterenol Hydrochloride Injection.

Isoproterenol hydrochloride injection is indicated to improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output and for treatment of bronchospasm occurring during anaesthesia.

Read Also

Zydus receives final approval from the USFDA for Tavaborole Topical Solution, 5%

The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).

Isoproterenol Hydrochloride Injection USP, 0.2 mg/mL and 1 mg/5 mL (0.2 mg/mL) had annual sales of USD 28.5 mn in the United States (IQVIA MAT Feb. 2023).

FPJ Shorts

Flood Fury In UP: Villagers Flee Homes, Last Rites Held In Lanes As Ghats Submerged

Project Jeevanjyot 2.0: Punjab To Conduct DNA Tests On Children Found Begging With Adults To Verify Parentage

30,000 Government Nurses In Maharashtra To Begin Indefinite Strike Amid Unmet Demands

Mumbai News: Citizens Launch Online Petition To Save Sanjay Gandhi National Park From Encroachments, Plastic And Stray Dog Threat

The group now has 362 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.